Summary
BeOne Medicines Ltd. (ONC) disclosed in its March 30, 2020, 8-K filing that the China National Medical Products Administration (NMPA) has suspended the importation, sales, and use of ABRAXANE® in China. This action stems from inspection findings at Bristol Myers Squibb's (BMS) contract manufacturing facility in the United States. Consequently, Celgene, a BMS company, has initiated a voluntary recall of all existing ABRAXANE stock in mainland China. This development represents a significant disruption for BeOne Medicines' operations in China concerning ABRAXANE, a key product likely contributing to revenue. The suspension and recall could lead to a material impact on sales and profitability for the period affected. Investors should monitor further communications from the company regarding the duration of the suspension, potential alternative supply sources, and the financial implications of this event.
Key Highlights
- 1China's NMPA has suspended importation, sales, and use of ABRAXANE® in mainland China.
- 2The suspension is based on inspection findings at BMS's contract manufacturing facility in the US.
- 3Celgene has initiated a voluntary recall of all existing ABRAXANE stock in mainland China.
- 4This action is a direct consequence of previous announcements made by the company.
- 5The filing confirms the ongoing impact of the manufacturing facility issues on product availability.
- 6Exhibit 104 contains the cover page of the 8-K filing in Inline XBRL format.